|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Transoma Medical Announces First Patient Enrollment in Clinical Study on Long-Term Cardiac Monitoring for Detection of Atrial Fibrillation after Cryptogenic Stroke
4/14/2009 9:04:49 AM
ST. PAUL, Minn.--(BUSINESS WIRE)--Transoma Medical, Inc., manufacturer of Sleuth AT™, the only wireless, automated implantable cardiac monitoring system with programmable and frequent electrocardiogram (ECG) sampling, announced the first enrollment and implant in a long-term study to monitor patients who have suffered a cryptogenic stroke (of unknown origin) to determine if atrial fibrillation (AF) is present. The implant was performed on April 10 by Dr. Emile Daoud, electrophysiologist, at Ohio State University Medical Center in Columbus. The company received FDA 510(k) marketing clearance for Sleuth AT, its next-generation product, on Feb. 11, 2009.
|
|
|
|
|
|
|
|
|
|
|